
Validea's guru fundamental report rates Johnson & Johnson (JNJ) at 77% using the Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with sustained growth potential. As a large-cap growth stock in the Biotechnology & Drugs industry, JNJ largely aligns with the model's criteria, passing tests for profitability, cash flow, and sales variance. However, it notably fails criteria related to advertising and research and development as a percentage of assets, positioning its score just below the 80% threshold typically indicating 'some interest' from the strategy.
Johnson & Johnson (JNJ) receives a moderately positive quantitative assessment from Validea's P/B Growth Investor model, scoring 77% based on Partha Mohanram's strategy. This score positions JNJ just below the 80% threshold that typically indicates initial interest from the model. The analysis highlights a dichotomy in the company's fundamentals: JNJ exhibits strong current operational health and stability, passing criteria for its book-to-market ratio, return on assets (ROA), cash flow from operations, and low variance in both ROA and sales. These factors suggest high-quality, consistent earnings. However, the model, which is designed to identify sustained future growth, flags JNJ for failing on two key forward-looking metrics: Advertising to Assets and Research and Development to Assets. For a large-cap firm in the Biotechnology & Drugs industry, these failures may indicate that, relative to its substantial asset base, current investment levels in marketing and innovation are not optimized for future outperformance according to this specific academic framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment